BIG
NBIX icon

Brooklyn Investment Group’s Neurocrine Biosciences NBIX Stock Holding History

Brooklyn Investment Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$652K Buy
4,947
+375
+8% +$49.8K 0.02% 837
2025
Q4 		$657K Buy
4,572
+2,539
+125% +$368K 0.03% 512
2025
Q3 		$255K Buy
2,033
+4
+0.2% +$542 0.03% 485
2025
Q2 		$255K Buy
2,029
+1,811
+831% +$208K 0.03% 497
2025
Q1 		$24.1K Sell
218
-13
-6% -$1.65K 0.01% 1068
2024
Q4 		$31.5K Buy
231
+115
+99% +$14.2K 0.01% 648
2024
Q3 		$13.4K Buy
+116
New +$15.9K ﹤0.01% 727

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brooklyn Investment Group's NBIX Position: Q1 2026 in Review

Brooklyn Investment Group increased its Neurocrine Biosciences (NBIX) stake by 8.2% in Q1 2026, buying an estimated $49.8K and bringing the position to 4,947 shares worth $652K. The position accounts for 0.02% of the portfolio, ranked #837.

Brooklyn Investment Group first reported a position in NBIX in Q3 2024 and has held it in 7 quarters since. The position peaked at $657K in Q4 2025. 697 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Brooklyn Investment Group held 4,947 shares of Neurocrine Biosciences worth $652K as of Q1 2026.
  • Brooklyn Investment Group bought 375 Neurocrine Biosciences shares in Q1 2026, an estimated $49.8K.
  • Neurocrine Biosciences made up 0.02% of Brooklyn Investment Group's portfolio in Q1 2026, its #837 holding.
  • Brooklyn Investment Group first reported a position in Neurocrine Biosciences in Q3 2024 and has held it in 7 quarters since.
  • Brooklyn Investment Group's Neurocrine Biosciences position peaked at $657K in Q4 2025.
  • 697 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Brooklyn Investment Group's 13F filing for Q1 2026, filed 29 Apr 2026.